妊娠糖尿病患者血浆 IL－1β水平变化与胰岛素抵抗的关系

目的：探讨妊娠糖尿病患者血浆白介素－1β（IL－1β）水平的变化及与胰岛素抵抗的关系。方法选取妊娠糖尿病组（GDM）65例,正常对照组（NC）55例,同时采集病史、进行体格检查并留取血浆,测定其空腹血糖、胰岛素、血脂和空腹 IL－1β的水平,采用 HOMA－IR 模型公式计算胰岛素抵抗指数,两因素间关系采用 Pearson 相关分析,多个变量间的分析采用多元逐步回归分析。结果 GDM 组 Fins、HOMA－IR 指数较 NC 组增高（ P ＜0．05）,HOMA－β指数较 NC 组降低（ P ＜0．05）,空腹血浆 IL－1β水平 GDM 组显著高于 NC 组（ P ＜0．01）;相关分析 HOMA－IR 指数与IL－1β、SBP、DBP、Fins、FPG、TC、TG、LDL－C 及 apo－B 呈正相关关系（ P ＜0．05）,与 HDL－C 呈负相关关系（ P ＜0．05）。校正 WHR 及 BMI 的影响后,HOMA－IR 指数与 IL－1β、DBP、Fins、FPG、TC、TG 及 LDL－C 呈正相关关系（ P ＜0．05）;与HDL－C 呈负相关关系（ P ＜0．05）。结论妊娠糖尿病患者血浆 IL－1β水平升高可间接反应胰岛素抵抗程度。     

右美托咪定辅助颈丛阻滞甲状腺手术的临床研究

目的 观察右美托咪定辅助颈丛阻滞甲状腺手术的麻醉效果及对血流动力学的影响.方法 40例颈丛神经阻滞甲状腺手术病人随机分为2组,D组右美托咪定组（20例）,C组0.9%氯化钠对照组（20例）.观察麻醉效果并记录颈丛阻滞前（T0）、切皮（T1）、分离腺瘤（T2）、手术结束 （T3） 等各时点的SBP、DBP、HR.结果 D组麻醉效果优于C 组（P〈0.05）.D组各时点SBP、DBP、HR较平稳.C组T1、T2、T3各时点SBP、DBP、HR较T0明显升高（P〈0.05）,D组T1、T2、T3各时点SBP、DBP、HR较C组明显下降 （P〈0.05）.结论 右美托咪定辅助颈丛阻滞甲状腺手术,其镇静、镇痛作用好,血流动力学稳定.     

缬沙坦联合辛伐他汀治疗高血压伴高血脂的临床观察

目的观察缬沙坦联合辛伐他汀治疗高血压伴高血脂的临床疗效。方法将88例高血压伴高血脂患者随机分为试验组和对照组各44例。试验组给予缬沙坦联合辛伐他汀治疗,对照组给予氨氯地平阿托伐他汀治疗,比较2组患者治疗前后的血压、血脂水平变化。结果2组治疗前SBP、DBP、TC、TG、LDL-C、HDL．C水平差异无统计学意义（P〉0．05）;治疗后,2组SBP、DBP、TC、TG、LDL—C水平均明显下降（P〈0．05）,HDL-C水平显著上升（P〈0．05）;2组间患者治疗后的SBP、DBP、HDL-C水平差异无统计学意义（P〉0．05）;试验组用药后的TC、TG、LDL—C水平明显低于对照组,差异有统计学意义（P〈0．05）。结论在高血压伴高血脂临床治疗中,应用缬沙坦联合辛伐他汀疗法,能有效降低患者的血压、血脂水平,疗效显著,安全性高,值得临床推广应用。     

不同剂量雷米芬太尼微量泵输注对气管插管血流动力学改变的影响

目的探讨不同剂量雷米芬太尼微量泵输注对气管插管血流动力学改变的影响。方法将120例择期行腹部手术患者随机分为三组,每组40例。在丙泊酚泵注患者意识消失后分别给予A、B和C组0．15、0．20及0．25μg／（kg·min）雷米芬太尼输注8min。记录诱导前（T0）、气管插管前1min（T1）、气管插管即刻（T2）、气管插管后3min（T,）及气管插管后5min（T4）血流动力学的改变。结果与哟相比,三组T1时点收缩压（SBP）、舒张压（DBP）及心率（HR）显著下降（P〈0．05）,A组SBP、DBP及HR显著高于B组及C组（P〈0．05）;A组T2-L时点SBP、DBP及HR均显著高于B组及C组（P〈0．05）。结论0．20及0．25μg／（kg·min）雷米芬太尼微量泵泵注8min可维持气管插管时血流动力学平稳。     

β—地中海盆血患者血脂及载脂蛋白分析

目的：观察β－地中海贫血患者血脂（TC、TG、HDL－C、LP（a)）及载脂蛋白（APOAI、APOB100）与健康人之间的变化情况。方法：采用酶法和免疫化学法对20例β－地中海贫血的患者和20例性别相同,年龄一致的健康人的血脂及载脂蛋白进行了测定。结果：除了APOAI值增高,差异具有显著意义（P＜0．05）外,其他各项指标（TC、TG、HDL－C、LP（a）、APOB100）与健康人比较均差异无显著意义（P＞0．05）。结论：提示可能β－地中海贫血患者APOAI增高具有抗动脉粥样硬化的血脂优势。     

原发性高血压伴左室肥厚患者血压昼夜节律、血压负荷及其变异性的研究

目的：探讨原发性高血压（EH）患者血压昼夜节律、血压负荷及血压变异性对左室肥厚（LVH）影响。方法：对确诊的60例EH患者行24h动态血压和超声心动图检测。结果：EH伴LVH与无LVH两组24h平均收缩压（SBP）及昼间平均SBP有显著性差异（P＜0．01，P＜0．05）；夜间平均SBP、平均舒张压（DBP）有显著性差异（P＜0．01，P＜0．05）。两组24h收缩压负荷（SBP load)及舒张压负荷（DBP load)有显著性差异（P＜0．05），昼间均无显著性差异（P＞0．05），夜间SBP load及DBP load均有显著性差异（P＜0．05）。昼间收缩压标准差（ABPVs)有显著性差异（P＜0．05），夜间ABPVs及舒张压标准差（ABPVd)有显著性差异（P＜0．05）。结论：原发性高血压伴左心室肥厚者其血压负荷及血压变异明显增大。夜间血压和左心室肥厚的关系更为密切。     

胰岛素与二甲双胍、罗格列酮联合治疗2型糖尿病

目的观察单纯胰岛素(InS)治疗、胰岛素加二甲双胍、胰岛素加罗格列酮三种方法治疗2型糖尿病(DM)的疗效。方法将60例2型DM患者分成三组,每组各20例,A组单纯采用胰岛素(诺和灵30R)治疗,B组用胰岛素(诺和灵30R)加二甲双胍治疗,C组胰岛素(诺和灵30R)加罗格列酮治疗,疗程均为3个月。3个月后观察各组糖基化血红蛋白(Hb A1c)血糖(FBS、PBS)、血脂(TC、TG、HDL)、体重指数(BMI)、收缩压(SBP)及舒张压(DBP)的改善情况。结果治疗后三组FBS、PBS、Hb A1c较治疗前明显下降(P<0.001),B、C两组TG、TC、HDL、SBP、DBP均有显著性改变(P<0.01),B组BMI较治疗前下降(P<0.05),而A组BMI、TG、TC、HDL、SBP、DBP无显著改变。结论运用二甲双胍或罗格列酮加胰岛素治疗2型DM比单纯用胰岛素治疗效果好。     

地尔硫卓在颈丛阻滞麻醉中的血流动力学稳定作用

目的研究地尔硫卓对颈丛阻滞麻醉引起的血流动力学变化的影响。方法 60例择期行甲状腺手术的女性患者随机平均分为地尔硫卓组(Dil组)和对照组(C组)。行一针法双侧颈浅丛和单侧颈深丛神经阻滞后10min后对血压升高增加、心率增快显著的患者,Dil组采用静脉注射地尔硫卓0·1mg/kg,继用输注泵以5μg/(kg·min)持续静脉输注;C组采用静脉注射硝酸甘油100μg,继用输注泵以0·5μg/(kg·min)持续静脉输注。记录麻醉前(T0)、颈丛阻滞后10min(T1)、20min(T2)、30min(T3)的SBP、DBP、HR,计算SBP与HR的乘积(RPP)。结果 C组在T1~T3时及Dil组在T1时的SBP、DBP和RPP均明显高于T0时,HR快于T0时,差异有统计学意义(P<0·05),C组在T2~T3时的SBP、DBP、RPP较T1时下降,HR较T1时增快,但差异无统计学意义(P>0·05);Dil组在在T2~T3时的SBP、DBP、RPP和HR与T1时相比较明显降低或减慢,差异有统计学意义(P<0·05),与T0时比较无统计学差异(P>0·05);在T2~T3时Dil组SBP、DBP、RPP和HR均较C组降低或减慢,差异有统计学意义(P<0·05)。结论地尔硫卓在颈丛阻滞麻醉过程中具有血流动力学稳定作用,可以缓解颈丛麻醉带来的血压升高、心率增快等副反应。     

体检人群超敏C反应蛋白与代谢综合征的相关性研究

目的：探讨体检人群超敏 C 反应蛋白（hs‐CRP）与代谢综合征（MS）的关系。方法选取健康体检者中体检数据完整的975例受检者,其中符合 MS 诊断的277例,采用秩和检验分析 MS组与非 MS 组间的各组分关系,应用 Spearman 秩相关分析 hs‐CRP 与 MS 各组分的相关性。结果 MS组 HDL‐C 水平低于非 MS 组,BMI 、SBP 、DBP 、hs‐CRP 、TC 、TG 、LDL‐C 、FPG 、ALT 、AST 水平均高于非 MS 组,差异有统计学意义（P＜0．05）。不同年龄段人群非 MS 组与 MS 组 hs‐CRP 水平均有差异（P＜0．05）。肥胖组 hs‐CRP 水平与低体质量组、正常体质量组、超重组比较明显升高（P ＜0．05）。hs‐CRP 水平与 BMI 、TC 、TG 、FPG 、ALT 、AST 、SBP 及 DBP 呈正相关;与 HDL‐C 呈负相关。结论hs‐CRP 水平与 MS 的发生、发展密切相关。     

卤虫中蛋白质和脂肪酸组成的研究

用毛细管气相色谱法、微量凯氏定氮法、氨基酸自动分析仪对卤虫中蛋白质和脂肪酸组成进行分析。结果表明，蛋白质含量比较高，富含18种氨基酸，包括8种必需氨基酸。色谱分离出32个峰。主要脂肪酸有C16：1（n－7），17．3％；C18：1（n－9），20％；C18：2（n－6），2．8％；C18：3（n－3），2．5％；C20：5（n-3），3．5％。     

Blood pressure responses to whole-body cold exposure: effect of carvedilol

OBJECTIVE: The aim of this study was to test the effects of carvedilol on blood pressure (BP) and heart rate (HR) during whole-body cold exposure in hypertensive and normotensive subjects. METHODS: Ten hypertensive and twelve normotensive subjects were exposed to cold (-15 degrees C, wind 3.5 m/s) three times for 15 min with a 1-week interval between the exposures. The study design was made according to a randomised double-blind, crossover method. Before the cold exposures the subjects ingested carvedilol or placebo once a day (carvedilol 12.5 mg/day for 2 days and then 25 mg/day for 5 days) for 1 week. The systolic (SBP) and diastolic (DBP) blood pressure and HR were measured every 3 min during the test procedures using an indirect ambulatory blood pressure monitor device (ABPM-02, Meditech Co.). RESULTS: In the hypertensive group, the cold exposure increased SBP/DBP from 119/75 mmHg to 143/96 mmHg during carvedilol treatment (P<0.001) and from 132/85 mmHg to 159/106 mmHg during placebo (P<0.001). In the normotensive group the cold exposure increased SBP/DBP from 112/72 mmHg to 142/93 mmHg during carvedilol treatment (P<0.001) and from 121/75 mmHg to 147/98 mmHg during placebo (P<0.001). In the hypertensive group, the levels of SBP, DBP and MAP (mean arterial pressure) were significantly lower with carvedilol than with placebo during the cold exposure although carvedilol did not affect the cold-induced rise of the BP. The BPs were lower also with carvedilol in the normotensive group than the placebo during the cold exposure, but the differences were smaller than in the hypertensive group. Carvedilol decreased the BP more the higher the initial mean SBP/DBP was with placebo during the cold exposure. CONCLUSION: Carvedilol reduced the BP during the cold exposure, especially in the hypertensive subjects but also in normotensive ones, without effect on the cold-induced rise of the BP.     

老年高血压患者7d家庭自测收缩压变异性与血管内皮功能的相关性

目的：探讨老年原发性高血压患者7 d 家庭自测血压变异性与血管内皮之间的相关性。方法对来自于健康体检中心体检的142例老年原发性高血压患者进行7 d 家庭自测血压监测及内皮细胞依赖性血管舒张功能（FMD）和内皮非依赖性血管舒张功能（NMD）检测。根据7 d 家庭自测血压变异性（用标准差表示）的三分位,将所有患者分为低变异性组、中变异性组及高变异性组3组。结果高变异性组 FMD 和 NMD 明显低于中及低变异性组,中变异性组明显低于低变异性组,P ＜0．05。FMD 及 NMD 与收缩压变异性（r 分别为－0．635及－0．448,P 均＜0．001）、舒张压变异性（r 分别为－0．187及－0．186,P 均＜0．001）呈负相关。多元线性回归分析显示,在用家庭自测平均收缩压及家庭自测平均舒张压进行校正后,收缩压变异性仍与 FMD 及 NMD 呈显著负相关。结论家庭自测血压变异增高可能是影响血管内皮功能失调的重要因素。     

Cardiovascular effects of two new calcium antagonists, PY 108-068 and PN 200-110, in conscious spontaneously hypertensive rats.

1. The acute cardiovascular effects of PY 108-068 and PN 200-110 were studied by means of a computerized analysis of the intra-aortic blood pressure (BP) recorded continuously for 26 h in conscious unrestrained spontaneously hypertensive rats. Both compounds were studied at three doses (50, 100 and 200 micrograms kg-1) and each dose was administered intravenously 5 times (09 h 00 min, 14 h 00 min, 19 h 00 min, 24 h 00 min and 09 h 00 min). Baroreflex sensitivity was measured 1 h following the last injection. 2. The two compounds were found to induce rapid (3 min) and dose-dependent falls in BP. After the first administration, these decreases reached -20% and -35% for systolic BP (SBP) and diastolic BP (DBP) respectively with PY 108-068 (200 micrograms kg-1) and -25% and -45% for SBP and DBP respectively with PN 200-110 (200 micrograms kg-1). 3. The duration of the reduction in BP increased with the dose and was much longer for PN 200-110 (180 min for SBP) than for PY 108-068 (20 min for SBP). 4. A tachycardia was associated with the decrease in BP which did not differ at 200 micrograms kg-1 between PY 108-068 (+ 108 beats min-1) and PN 200-110 (+ 103 beats min-1). Baroreflex sensitivity was not significantly increased by either drug. 5. The 5 repeated injections of PY 108-068 and PN 200-110 evoked similar responses. 6. In conclusion, both compounds exhibited marked hypotensive properties.(ABSTRACT TRUNCATED AT 250 WORDS)     

Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients

OBJECTIVE: To assess the long-term antihypertensive efficacy and acceptability of indapamide SR 1.5 mg in elderly hypertensive patients (> or = 65 years). STUDY DESIGN: Open, 12-month, follow-up study of 444 patients, treated with indapamide SR, who were responders and/or achieved target BP levels following a 3-month, randomised, controlled, double-blind short-term comparison of indapamide SR versus hydrochlorothiazide 25 mg and amlodipine 5 mg. RESULTS: The long-term decrease in systolic blood pressure (SBP)/diastolic blood pressure (DBP) after 12 months follow-up with indapamide SR was -24.0/-13.1 mmHg from baseline (M0). The percentage of patients that achieved target BP levels (DBP < 95 mmHg, SBP < or = 160 mmHg) was 80.1% [84.3% for isolated systolic hypertension (ISH) subgroup], and the response rate (BP < 140/90 mmHg or decrease in supine diastolic BP > or = 10 mmHg or in supine systolic BP > or = 20 mmHg) 81.5%. Blood pressure (BP) remained stable throughout the 12 months follow-up period (M3-M15), whatever the previous treatment received during the 3-month, doubleblind period (M0-M3). Clinical and biological acceptability was good. A low occurrence of withdrawals (7.2%), was reported. CONCLUSION: Over the course of the long-term, 12-month follow-up study, indapamide SR was shown to be an effective and well tolerated antihypertensive therapy, even after a switch from amlodipine or hydrochlorothiazide, in patients aged 65 years-80 years with systolo-diastolic hypertension (SDH) or ISH.     

Antihypertensive effect of lisinopril assessed by 24-hour ambulatory monitoring: a double-blind, placebo-controlled, cross-over study.

The antihypertensive effect of the angiotensin-converting enzyme (ACE) inhibitor lisinopril administered in a single dose of 20 mg was evaluated by ambulatory blood pressure monitoring (ABPM) in a double-blind, placebo-controlled, cross-over study. Twenty-four patients (21 men and 3 women, mean age 52 +/- 6 years) with mild to moderate hypertension were included in the study and randomly assigned to two consecutive treatments with lisinopril 20 mg and placebo, each administered for 4 weeks. On the last day of each treatment, BP was assessed by noninvasive 24-h ABPM. BP was significantly lower after lisinopril than after placebo in a 24-h period (mean 24-h systolic BP (SBP) with lisinopril 120 +/- 7 mm Hg and with placebo 135 +/- 9 mm Hg; mean day SBP with lisinopril 125 +/- 3 mm Hg and with placebo 142 +/- 5 mm Hg; mean night SBP with lisinopril 112 +/- 4 mm Hg and with placebo 124 +/- 6 mm Hg; mean 24-h diastolic BP (DBP) with lisinopril 76 +/- 6 mm Hg, and with placebo 87 +/- 8 mm Hg; mean day DBP with lisinopril 80 +/- 3 mm Hg and with placebo 93 +/- 4 mm Hg; mean night DBP with lisinopril 69 +/- 2 mm Hg and with placebo 79 +/- 5 mm Hg, p less than 0.001). Mean 24-h, mean day, and mean night heart rate (HR) did not differ significantly between placebo and lisinopril treatments. Repeated-measures analysis of variance (ANOVA) showed a significant influence on SBP (p less than 0.001) and DBP (p less than 0.001) throughout the treatment.(ABSTRACT TRUNCATED AT 250 WORDS)     

Can losartan improve cardiac performance during the treadmill exercise test in hypertensive subjects?

Systolic blood pressure (SBP) normally increases during exercise. This increase is frequently exaggerated in hypertensive individuals. The aim of our study was to evaluate the antihypertensive effects of losartan at peak exercise and on cardiac performance during the treadmill test in individuals with essential hypertension. Forty subjects with a mean age of 44.2 +/- 12.4 years and with mild-to-moderate essential hypertension were enrolled. After a 14-day washout period, all selected subjects were given a treadmill exercise test using the modified Bruce protocol for exercise. The test was performed at the end of the washout period (step 0), again after 1 month (step 1), after 3 months (step 2) and after 6 months (step 3) of losartan administration (50 mg/daily per oral). Heart rate, SBP and diastolic blood pressure (DBP) were measured at rest and at maximal exercise. Exercise duration and double product were also recorded. In all patients who completed the study, a significant reduction from baseline in SBP at rest was found at 3 and 6 months (p < 0.05). No significant reduction from baseline in SBP at peak exercise was observed. No significant changes from baseline were found in double product, DBP, heart rate or exercise time. The results of our study suggest that losartan is effective in reducing blood pressure only at rest but is unable to improve exercise BP response or cardiac performance in subjects with mild-to-moderate essential hypertension.     

Long-acting lacidipine versus short-acting nifedipine in the treatment of asymptomatic acute blood pressure increase

We compared antihypertensive efficacy and safety of a single administration of equipotent doses of lacidipine versus nifedipine in the hypertensive urgencies. Twenty-nine asymptomatic essential hypertensive patients (nine men, 20 women) with a mean age of 55.03+/-11.19 years and baseline diastolic blood pressure (DBP) of > or =120 mm Hg after resting 30 min, not taking antihypertensive drugs for the last 24 h, were randomized in a single-blind fashion to receive lacidipine, 4 mg (LCD, 15 patients) or short-acting nifedipine, 20 mg (NFD, 14 patients) in a single dose. Blood pressure (BP) and heart rate (HR) were taken every 30 min during the first 8 h and every 2 h until 24 h of follow-up. Baseline BP values were similar in the two groups (LCD, 222.5+/-32.8/124.6+/-8.4 mm Hg vs. NFD, 215.9+/-20.6/128+/-7.7 mm Hg; p = NS). Both drugs promoted a significant reduction of systolic blood pressure (SBP; 169.6+/-27.8 vs. 170.6+/-25.3 mm Hg) and diastolic blood pressure (DBP; 104.1+/-16 vs. 102.9+/-12.4 mm Hg) after 8 h. However, either SBP (165+/-27.3 vs. 190.6+/-18.2 mm Hg; p = 0.008) and DBP (99.9+/-12.3 vs. 117.2+/-11.4 mm Hg; p = 0.001) were significantly higher in the NFD group after 24-h dosing. Eleven patients in the LCD group had a decrease in BP >25% of the baseline value both 8 and 24 h after the dose. Although 10 patients showed the same response in the NFD group 8 h after the dose, only four patients maintained these values at 24 h. One patient treated with NFD had a transient cerebrovascular ischemic attack. No adverse effects were observed in the LCD group. We conclude that the long-acting calcium antagonist lacidipine was more effective than the short-acting nifedipine in both controlling BP and maintaining this BP reduction over 8 h in essential hypertensive patients with acute asymptomatic BP increase.     

ET-1 Lys198Asn和eNOS Glu298Asp基因多态性与原发性高血压及硝苯地平降压疗效的相关性

目的　研究安徽省 1个高血压人群中内皮素 1 (ET 1 )基因位于第 5号外显子的第 1 98位密码子G/T多态性导致的赖氨酸 /天冬酰胺 (Lys1 98Asn)突变以及内源性一氧化氮合成酶 (eNOS)基因第 2 98位密码子的G/T多态性导致的谷氨酸 /天冬氨酸 (Glu2 98Asp)突变与原发性高血压及抗高血压药物硝苯地平降压疗效的相关性。方法　 1 1 0 8例初诊或已停药 2wk以上的原发性高血压病人 ,口服硝苯地平类药物 (拜新同 30mg·d- 1 ) 1 5d。分别按照收缩压及舒张压的降压效果 ,选取降压效果最好及最差的各 1 0 0例病人。这样 ,共 2 93例病人入选该研究。基因型测定采用PCR RFLP方法。分别按收缩压和舒张压 ,对两极端组病人基因多态性与基线血压及降压效果进行分析。结果　在两组极端组组成的总人群中 ,ET 1基因多态性中TT纯合子基因型受试者的基线舒张压〔DBP =(1 0 3 3± 1 6)mmHg〕(1kPa =7 5mmHg)高于带有G等位基因 (GG/GT)的受试者DBP =(99 4± 0 5)mmHg〕 (P =0 0 2 )。ET 1的Lys1 98Asn多态性和eNOS的Glu2 98Asp多态性与拜新同降压效果的关系 ,无论以收缩压还是以舒张压来分 ,均无显著相关性。结论　在该研究的高血压人群中ET 1的Lys1 98Asn多态性与基线舒张压相关。ET 1Lys1 98Asn多态性和eNOSGlu2 98Asp多态性?     

Effect of a new calcium antagonist, tiapamil, in hypertension of the elderly.

The antihypertensive effect of a single oral dose of tiapamil (450 mg) and placebo were compared in a single blind randomized cross-over study in 10 71-86 year old hypertensive patients. Blood pressure (BP) and heart rate (HR) were recorded every 15 min for 12 h by an automatic device. Tiapamil led to a decrease in mean daytime systolic (SBP) and diastolic (DBP) BP from 171 +/- 12/98 +/- 10 mm Hg to 159 +/- 11/90 +/- 9 mm Hg (P less than 0.001) without significant variation in HR. Thereafter patients received tiapamil 450 twice daily; by the seventh day of treatment mean daytime SBP and DBP were 155 +/- 13/85 +/- 14 mm Hg (P less than 0.001 vs placebo). The hourly mean values of SBP recorded for 8/12 h (first tiapamil day) and 10/12 h (seventh tiapamil day) were significantly lower than the corresponding values after placebo. We conclude that tiapamil in the elderly exerts a sustained antihypertensive effect lasting 12 h or more, with only minor variations in HR. This effect predominates on systolic pressure and is significant from the first dose.     

拉萨藏族人群尿电解质及氨基酸排泄与血压水平的关系

随机抽取拉萨市49—54岁年龄组108名(男性42人,女性66人)藏族人群,测定身高、体重、血压及24小时尿钠、钾、钙、镁和氨基酸等生物学指标,以评价藏族人群独特的饮食习惯与血压水平之关系.结果显示:平均收缩压、舒张压、尿钠和钠/钾比高;尿钾、钙、镁、牛磺酸及1—甲基组氨酸排泄量低.尿镁与收缩压呈负相关;3—甲基组氨酸与舒张压呈负相关.尿镁及3—甲基组氨酸作为独立因素分别进入收缩压及舒张压多元回归方程.收缩压、舒张压与尿钠呈负相关、与体重指数呈正相关,但相关系数均无显著意义.结果提示:饮食中的多种营养因素包括低钾、低镁和低3—甲基组氨酸摄入可能与血压水平和高血压患病率高有一定关系.改善饮食结构可有利于正常血压的调节和高血压的防治.